The Trump administration defunded the National Institute of Health's MOSAIC grant program, which launched the careers of scientists from diverse backgrounds.

Two new studies suggest that Parkinson's disease can potentially be treated with stem cells placed in a patient's brain.

Surgeons at NYU Langone Health in New York City had to remove a genetically modified pig kidney from Towana Looney, 53, of Gadsden, Ala., because her body rejected the organ. She's back on dialysis.

Scientists have recreated a pathway that senses pain, using clusters of human nerve cells grown in a dish.

Many AI products claim to deliver mental health therapy, but with little quality control. But new research suggests with the right training, AI can be effective at helping people.

New tests of blood and spinal fluid can identify people experiencing memory loss from Alzheimer's disease.

For people with gambling disorder, the proliferation of gambling opportunities makes it difficult to fight their addiction. Investment in treatment lags behind other addiction disorders.

Mia Love, the first Black Republican woman elected to Congress, died three years after being diagnosed with glioblastoma, a brain cancer that is nearly always fatal.

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop Wednesday. That has left many patients wondering what to do next.

They're pushing for more funding to find effective treatments. Researchers are finally starting to make headway but have a way to go.

A man living with paralysis felt his index finger for the first time in three years, thanks to technology that reconnected his brain and body.

Dr. Jay Bhattacharya, a Stanford professor of health policy, appears before the Senate HELP committee, which will vet his nomination to become the next director of the National Institutes of Health.

Myra Solano Garcia, who has Alzheimer's, says the drug Kisunla may be one reason she can still drive, cook, and sing.

Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband isn't sure if it made a difference.

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy of the weight-loss medicines it mailed to patients.